Carbidopa is a peripheral decarboxylase inhibitor typically administered in combination with levodopa to manage the motor symptoms of Parkinson's disease. By inhibiting the aromatic L-amino acid decarboxylase… Read more















![Chemical structure of 1-Oxa-2-azaspiro[2.5]octane](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F185-80-8-1-Oxa-2-azaspiro2.5octane.png&w=3840&q=75)


































Carbidopa is a peripheral decarboxylase inhibitor typically administered in combination with levodopa to manage the motor symptoms of Parkinson's disease. By inhibiting the aromatic L-amino acid decarboxylase enzyme in peripheral tissues, this pharmacological agent prevents the premature breakdown of levodopa, thereby increasing its bioavailability to cross the blood-brain barrier and facilitate dopamine production in the central nervous system. This catalogue provides a comprehensive range of Carbidopa reference standards, including the active pharmaceutical ingredient, process-related impurities, degradation products, and metabolites. These high-quality materials are essential for pharmaceutical laboratories to perform accurate impurity profiling, rigorous method validation, and routine quality control testing. Additionally, the inclusion of stable isotope labelled compounds enables precise quantification in complex bioanalytical studies. By utilizing these characterized standards, researchers can ensure analytical reliability and consistency throughout the drug development and regulatory compliance lifecycle.